Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001235802-22-000035)

Filing Details

Accession Number:: 0001235802-22-000035
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-03-02 16:15:19
Reporting Period:: 2022-02-28

Accepted Time:: 2022-03-02 16:15:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1427570	Reshape Lifesciences Inc.	RSLS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1181166	Thomas Stankovich	1001 Calle Amanecer San Clemente CA 92673	Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Disposition	2022-02-28	3,658	$1.06	355,194	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.